

# Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Protective effects of apigenin on furan-induced toxicity in mice**

Formatted: Font color: Auto

Formatted: Font color: Auto

2

3 **Enting Wang<sup>a</sup>, Fang Chen<sup>b</sup>, Xiaosong Hu<sup>b</sup>, and Yuan Yuan<sup>a\*</sup>**

Formatted: Font color: Auto

4

Formatted: Font color: Auto

5

*a College of Quartermaster Technology, Jilin University, Changchun, China, 130062*

6

*b College of Food Science & Nutritional Engineering, China Agricultural University, Beijing, China,*

7

*100083*

8

9 Running title: Protective effect of apigenin against furan

10

---

\* Corresponding author at: College of Quartermaster Technology, Jilin University, Changchun, China, 130062, Tel: 0086-431-87836376, E-mail address: [yuan yuan1024@gmail.com](mailto:yuan yuan1024@gmail.com) (Y. Yuan)

11 **Abstract**

12 ▲ Furan, a food contaminant formed by heating, is possible carcinogenic to humans. In this study,  
13 we discussed the effect of administration of apigenin on furan-induced toxicity by determining the  
14 ROS content, oxidative damage, cytokines, DNA damage, and the liver and kidney damage of  
15 mice model. ▲ Our data showed that the administered apigenin of 5, 10, and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> could  
16 decrease the toxicity induced by furan in different extent. On the one hand, apigenin has ability to  
17 increase the oxidative damage indexes of glutathione (GSH), glutathione S-transferase (GST),  
18 superoxide dismutase (SOD) activities but decrease myeloperoxidase (MPO) activities, and maleic  
19 dialdehyde (MDA) content in the liver and kidney of mice treated by furan. On the other hand, it  
20 could decrease cytokines of tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1 $\beta$ , interleukin  
21 (IL)-6 content, increase interleukin (IL)-10 in the serum of furan-treated mice. Meanwhile,  
22 different concentrations of apigenin could decrease the ROS content, DNA damage index of  
23 8-hydroxy-desoxyguanosine (8-OHdG) content, and decrease the liver and kidney damage indexes  
24 of aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactic dehydrogenase (LDH)  
25 activities, as well as blood urea nitrogen (BUN) and creatinine content in furan-treated mice..The  
26 protective effects of apigenin against furan-induced toxicity damage were ▲ mainly due to its  
27 excellent ability to scavenge free radicals and lipid oxidation inhibition ability. This is important  
28 when considering the possibility of using apigenin as a dietary supplement in diets for a beneficial  
29 application in the chemoprevention against furan toxicity.

30 **Keywords:** Furan, apigenin, radicals, antioxidant effect, protective effect, toxicity

31 ▲

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

## 32 Introduction

33 Food processing involves many reactions, and many contaminants are generated during the  
34 heating of foods. Furan is just a typical food contaminant which could have harmful effects on the  
35 health of the human population. In 2004, the US FDA reported that furan occurred in a number of  
36 canned and jarred foods which especially underwent heat-processed.<sup>1</sup> Besides, almost all of the  
37 baby food sold in jars and cans contained detectable furan. US FDA (2004) internet data showed  
38 that furan concentrations in staple foods were below 18.8 ng g<sup>-1</sup>, and in supplement foods were up  
39 to 108 ng g<sup>-1</sup>.<sup>1</sup> In some certain foods, the level of furan is even higher than 5000 ng g<sup>-1</sup>, especially  
40 in roasted coffee powder.<sup>2</sup> In our previous study, we found that furan was detected in almost all  
41 analyzed samples in 191 selected food products obtained from the Chinese markets, and the higher  
42 contents of furan were detected in traditional Chinese liquor (61.63 ng g<sup>-1</sup>), coffee (71.36 ng g<sup>-1</sup>),  
43 tea (68.28 ng g<sup>-1</sup>) and pickle (85.63 ng g<sup>-1</sup>).<sup>3</sup> In recent years, the formation mechanisms of furan  
44 have been raised by some researchers. The potential mechanisms about the formation of furan may  
45 be due to the thermal degradation and rearrangement of sugars, amino acids, and the oxidation by  
46 the reactive oxygen species (ROS) or lipoxygenase of polyunsaturated.<sup>4-8</sup> However, up to now, no  
47 conclusive remarks have been established regarding the main mechanism and major precursor of  
48 furan formation in different kinds of food processed at high temperatures.<sup>9</sup>

49 The toxicity of furan *in vitro* and *in vivo* has also been studied by some researches. The  
50 International Agency for Research on Cancer (IARC) has classified furan as a possible human  
51 carcinogen (Group 2B).<sup>10</sup> Furan has also been known as being both hepatotoxic and carcinogenic in  
52 rats and mice by the National Toxicology Program (NTP).<sup>11</sup> In 90 days of gavaging experiments  
53 about the lower dose of furan, which was close to the estimated human exposures, a NOAEL of

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

54 0.12 mg kg<sup>-1</sup> bw was derived in the current study.<sup>12</sup> Selmanoğlu et al. investigate the effects of  
55 orally administered furan on liver and kidney in growing Wistar male rats for 90 days by determination  
56 of biochemical, morphological, histopathological and histomorphometrical examinations. Its results  
57 shown that furan may cause effects on the liver and kidney, and also could cause severe  
58 histopathological changes in the kidney in growing male rats.<sup>13</sup> As for the mechanistic aspects of the  
59 carcinogenicity of furan, studies have suggested that furan could act by both genotoxic and  
60 non-genotoxic mechanisms. More studies will be necessary in order to draw more precise  
61 conclusions concerning this issue.<sup>9</sup>

62 Since the toxicity of furan has harmful effects on the health of human, it is important to control  
63 or reduce the furan toxicity to humans. Recently, some natural bioactive components play  
64 important roles in controlling toxicity of the contaminants in mouse model. Zhang et al. and Wu et  
65 al. found that allicin could effectively reduce the toxicity induced by acrylamide; salidroside could  
66 protect the mice from the damage induced by furan toxicity.<sup>14-16</sup> These results of recent studies as  
67 well as our previous study have stimulated our interest in investigating the protective effects of  
68 some natural bioactive components against furan-induced toxicity *in vivo* in mouse.

69 Apigenin is a 4', 5, 7-trihydroxy flavones, widely found in a variety of fruits, vegetables, beans  
70 and tea. Apigenin possesses various pharmacological functions such as controlling apoptosis gene,  
71 inhibiting the expression of proto-oncogenes, inhibiting cancer cell proliferation, as well as  
72 inhibiting cancer cell invasion and metastasis.<sup>17-20</sup> Yang et al. investigate the protective effect of  
73 apigenin on acetaminophen-induced mouse acute liver injury and its potential mechanisms, which  
74 concluded that apigenin could protect against acetaminophen-induced acute liver injury in mice,  
75 and the mechanisms might be associated with enhancing hepatic GSH content via increment of

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

76 GR activity.<sup>21</sup> However, no study has evaluated the protective effects of apigenin treatment against  
77 furan-induced toxicity damage using a mouse model. The present study tried to reveal the  
78 protective effect of apigenin from ROS content, oxidative damage, cytokines, DNA damage, and  
79 liver and kidney damage in furan-treated mouse in the absence or presence of apigenin to test the  
80 protective effect of apigenin against furan-induced toxicity. The antioxidant activity of apigenin  
81 was also evaluated in our present study. The dose of furan was chosen according to the 2-year  
82 study conducted by NTP (1993), and the doses of apigenin were on the basis of pre experiment we  
83 did before.<sup>11</sup>

Formatted: Font color: Auto

## 84 **Materials and methods**

Formatted: Font color: Auto

### 85 **Materials**

86 Furan (CAS: 110-00-9, purity>98.0%) and apigenin (520-36-5, purity>99%) were purchased  
87 from Sigma-Aldrich (St. Louis, Mo., U.S.A.). Apigenin was dissolved in normal saline to give a  
88 final concentration of 0.5, 1 and 2 mg mL<sup>-1</sup>, respectively. Furan was diluted in normal saline to  
89 give a final concentration of 5 mg mL<sup>-1</sup>. The dosing volumes of apigenin and furan solutions were  
90 based on each animal's body weight, on a basis of a volume of 0.2 mL for a mouse of 20 g.

### 91 **Animals and experimental design**

Formatted: Font color: Auto

92 Fifty male healthy BALB/c mice (weighing 20 ± 5g) aged 4 to 5 weeks were utilized in this  
93 study, and they were provided by Laboratory Animals Center of Jilin University (Changchun,  
94 China). The research was carried out in accordance with the Guideline for Animal  
95 Experimentation of Jilin University (ChangChun, China). Animals were housed (10 mice each  
96 cage) in an air-conditioned room at 22 ± 2 °C and 30 ± 10% relative humidity. The animals were  
97 observed for general condition for 7 days during the quarantine and acclimation period to confirm

Formatted: Font color: Auto

98 that there were no abnormalities.

99 After a quarantine period of 7 days, 50 mice were randomly divided into five groups, each  
100 consisting of ten animals. Group I was treated with saline by oral gavage for 14 consecutive days  
101 and was denoted as the control group. Group II was treated intragastrically by gavage with saline  
102 for 7 consecutive days. On the 8<sup>th</sup> day, after the oral gavage saline, the mice were intraperitoneal  
103 injected with furan solution (8 mg kg<sup>-1</sup> bw d<sup>-1</sup>) for another 7 days and denoted as the Group furan.

104 The dose of furan was chosen according to the 2-year study conducted by NTP (1993).<sup>11</sup> Groups  
105 III, IV, and V were treated intragastrically by gavage with apigenin (5, 10 and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup>),  
106 respectively, for 7 days (once daily). On the 8<sup>th</sup> day, Groups III-V were administered  
107 intragastrically by gavage with apigenin (5, 10 and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup>) and intraperitoneal injected  
108 with a single dose of furan (8 mg kg<sup>-1</sup> bw d<sup>-1</sup>) for another 7 days. The bodyweight of the animals  
109 was measured daily and the doses of furan and apigenin were recorded according to the body  
110 weight of the animals.

111 On the 15<sup>th</sup> day, the animals were sacrificed within 24h after the last treatment, the whole blood  
112 of mice was collected into heparinized test tubes and centrifuged at 2500 × g for 15 min at 4 °C to  
113 separate serum, and the serum was stored at -70 °C freezer for further analysis. The kidney and  
114 liver were excised immediately from the mice, washed thoroughly with ice-cold normal saline.  
115 The tissues were homogenized with 10% pre-chilled normal saline in a tissue homogenizer, and  
116 then centrifuged at 2500 × g for 10 min at 4 °C. The supernatant was used for subsequent  
117 biochemical analyses.

#### 118 **ROS assay**

119 The ROS content of mice in the serum was detected by the commercial ELISA kits, which was

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

120 described by the reference of Zhang et al. (2013).<sup>15</sup>

Formatted: Font color: Auto

### 121 **Oxidative damage assay**

Formatted: Font color: Auto

122 The oxidative damage was evaluated by the activities of GSH, GST, SOD, MPO, and the  
123 content of MDA in the serum, which were detected by the commercial kits obtained from Beijing  
124 Dingguo Changsheng Biotechnology Co., Ltd. (Beijing, China) according to the manufacturer's  
125 instructions. The detail of the methods was described by the reference of Zhang et al. (2013).<sup>15</sup>

Formatted: Font color: Auto

### 126 **Cytokine assay**

Formatted: Font color: Auto

127 The cytokines in the serum of treated mice were evaluated by the changes of cytokine content,  
128 TNF- $\alpha$ , (IL)-1 $\beta$ , (IL)-6 and (IL)-10, which was described by the reference of Zhang et al. (2013).<sup>15</sup>

Formatted: Font color: Auto

### 129 **DNA damage assay**

Formatted: Font color: Auto

130 The contents of DNA damage was evaluated by the change of 8-OHdG in the serum by the  
131 commercial ELISA kits, which was obtained in Beijing Dingguo Changsheng Biotechnology Co.,  
132 Ltd. (Beijing, China). The method was also described in the reference of Zhang et al. (2013).<sup>15</sup>

Formatted: Font color: Auto

### 133 **The damage of liver and kidney assay**

Formatted: Font color: Auto

134 The activities of AST, ALT, LDH and the content of BUN and creatinine, as well as protein  
135 content were determined by commercial kits obtained from Beijing Dingguo Changsheng  
136 Biotechnology Co., Ltd. (Beijing, China) according to the manufacturer's instructions.

Formatted: Font color: Auto

### 137 **Antioxidant activity analysis of apigenin**

Formatted: Font color: Auto

138 The antioxidant analysis of apigenin was evaluated by scavenging ABTS radical, hydroxyl  
139 radical ( $\bullet$ OH), DPPH radical, and superoxideanion ( $\bullet$ O<sub>2</sub><sup>-</sup>), which were followed by the method of  
140 Yuan et al (2013).<sup>16</sup> The lipid oxidation inhibition assay of apigenin was measured using the  
141 method of Muñiz-Márquez et al. (2013).<sup>22</sup>

Field Code Changed

Formatted: Font color: Auto

Field Code Changed

Formatted: Font color: Auto



## 142 **Statistical analysis**

143 Statistical analysis was performed using SPSS 11.5 software (Chicago, USA). The significance  
144 of difference was calculated by one-way ANOVA test, and the results with  $p < 0.05$  were  
145 considered to be statistically significant. Graphs were drawn with OriginPro 8.0 software  
146 (OriginLab Corporation, Northampton, MA, USA).

## 147 **Results**

### 148 **Effect of apigenin on the ROS content**

149 We examined the effect of apigenin on the ROS content of furan-treated mice by using an  
150 ELISA kit. As shown in Fig. 1, the lowest ROS content ( $68.78 \pm 0.56 \text{ U mL}^{-1}$ ) was observed in the  
151 control group. The ROS content was significantly increased in the furan-treated group compared  
152 with those in the control group ( $p < 0.05$ ). The highest level of ROS ( $181.71 \pm 3.55 \text{ U mL}^{-1}$ ) was  
153 observed when the mice were treated with furan alone. The ROS content then decreased  
154 accordingly with the increase of apigenin concentrations at the range of 5 to 20  $\text{mg kg}^{-1} \text{ bw d}^{-1}$ .  
155 The administration of apigenin at concentrations of 5, 10, and 20  $\text{mg kg}^{-1} \text{ bw d}^{-1}$  significant  
156 reduced the ROS content by 15.0%, 30.9%, and 50.5%, respectively, compared to the group  
157 treated by furan. But the ROS content in the groups treated with 20  $\text{mg kg}^{-1} \text{ bw d}^{-1}$  apigenin was  
158 still markedly higher than that in control group ( $p < 0.05$ ).

### 159 **Effect of apigenin on the oxidative damage in the liver and kidney**

160 The effect of apigenin and furan on the oxidative damage in the liver and kidney of mice was  
161 evaluated by the indexes of GSH, GST, SOD, MPO, as well as the content of MDA, which were  
162 shown in Fig. 2 (A-E). The treatment of furan caused significant reduction of GSH, GST, and  
163 SOD activities in the livers and kidneys of male Balb/C mice, respectively, when compared to

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

164 control group ( $p < 0.05$ ). Enhancement of GSH level was observed in the groups treated with 5 mg  
165  $\text{kg}^{-1} \text{bw d}^{-1}$ , 10  $\text{mg kg}^{-1} \text{bw d}^{-1}$ , and 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$  of apigenin, respectively, compared with  
166 those treated by furan alone ( $p < 0.05$ ). As for the activity of GST and SOD, similar trend was  
167 found to the change of GSH. The administration of 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$  of apigenin, results in a  
168 significant elevation of GST activity compared to furan group, which increased by 45.42% and  
169 78.6% in liver and kidney respectively, and also the SOD activity increased by 114.52% in liver  
170 and 108.40% in kidney. Increase of MPO activity and MDA content were observed in the group  
171 treated by furan compared with that of control group ( $p < 0.05$ ). However, treatment with different  
172 doses of apigenin have decreased significantly MPO activity and MDA content both in liver and  
173 kidney compared to that of furan-treated mice ( $p < 0.05$ ) in different extent.

#### 174 **Effect of apigenin on the cytokines**

175 Four cytokines were detected for evaluating the effect of apigenin on the immunologic injury  
176 induced by furan, which were interleukins (IL)-6, (IL)-10, (IL)-1 $\beta$ , and TNF- $\alpha$ . As shown in  
177 Table 1, administration of furan showed significant increase of the content of (IL)-6, (IL)-1 $\beta$ , and  
178 TNF- $\alpha$ , and significant reduction of (IL)-10 content compared to the control group ( $p < 0.05$ ).  
179 Through the administration of apigenin with the dose of 5, 10, and 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$ , the content  
180 of (IL)-6 was effectively reduced ( $p < 0.05$ ), while the treatment of 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$  of apigenin  
181 effectively reduced the (IL)-6 level from  $82.08 \pm 0.94 \text{ pg mL}^{-1}$  to  $46.67 \pm 0.89 \text{ pg mL}^{-1}$  close to that  
182 of the furan-treated group ( $p < 0.05$ ). Meanwhile, the apigenin concentration of 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$   
183 was also found to be very effective in causing drastically decrease on the level of (IL)-1 $\beta$  and  
184 TNF- $\alpha$  ( $p < 0.05$ ). After treated with 20  $\text{mg kg}^{-1} \text{bw d}^{-1}$  apigenin, the level of TNF- $\alpha$  and (IL)-1 $\beta$   
185 in serum decreased by 30.97% and 43.80% respectively compared to furan group. On the

Formatted: Font color: Auto

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

186 contrary, the (IL)-10 levels of the groups treated with 5, 10, and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> of apigenin  
187 showed values of 109.16 ± 5.57, 123.21 ± 3.56, and 144.64 ± 3.41 pg mL<sup>-1</sup>, respectively, which  
188 were significantly higher than those in the furan treated group (*p* < 0.05). When the mice were  
189 treated with 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> of apigenin, its level of (IL)-10 was nearly back to the level of the  
190 control group.

### 191 **Effect of apigenin on the DNA damage**

192 To evaluate the effect of apigenin on the DNA damage in the serum of furan-treated mice, we  
193 assessed the changes of 8-OHdG content with different concentrations of apigenin. As shown in  
194 Fig. 3, after being treated with furan (8 mg kg<sup>-1</sup> bw d<sup>-1</sup>) for 7 days, a significant increase of  
195 8-OHdG content was observed compared to the control group (*p*<0.05), which reached at 33.74 ±  
196 1.04 ng mL<sup>-1</sup>, nearly three times higher compared with the control group. After being treated with  
197 different concentrations of apigenin, the effect of furan on 8-OHdG content was exhibited  
198 significantly, with 8-OHdG value 24.35 ± 1.30 ng mL<sup>-1</sup> for 5 mg kg<sup>-1</sup> bw d<sup>-1</sup>, 17.64 ± 0.63 ng mL<sup>-1</sup>  
199 for 10 mg kg<sup>-1</sup> bw d<sup>-1</sup> and 14.29 ± 0.42 ng mL<sup>-1</sup> for 20 mg kg<sup>-1</sup> bw d<sup>-1</sup>, respectively.

### 200 **Effect of apigenin on the damage of liver and kidney**

201 The effect of apigenin on the damage of liver and kidney in the serum of furan-treated mice was  
202 evaluated by the parameters of AST, ALT, LDH, BUN and creatinine. As shown in Table 2,  
203 pretreatment with the doses of 8 mg kg<sup>-1</sup> bw d<sup>-1</sup> of furan significantly elevated the activities of  
204 AST, ALT, LDH, and the levels of BUN and creatinine compared to the control group (*p*<0.05).  
205 The activities of AST and ALT have been considered as effective indicator of hepatic injury for a  
206 long time. In the current study, pretreatment with apigenin dramatically reduced the AST and ALT  
207 activities in the serum compared to the furan-treated group (*p*<0.05). As for the activity of AST,

Field Code Changed

Formatted: Font color: Auto

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

208 when the mice were treated with 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> of apigenin, the activity of AST (12.79±0.94 U  
209 L<sup>-1</sup>) was still significant higher than it in control group (8.98±0.37 U L<sup>-1</sup>) (*p*<0.05). Meanwhile, the  
210 group treated with 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> of apigenin showed the most effective protective effect from  
211 hepatic injury induced by furan, with the values of ALT activity of 14.53±0.65 U L<sup>-1</sup>, nearly back  
212 to the level of the control group. The effect of apigenin on the damage of the kidney in the serum  
213 of furan-treated mice was evaluated by the changes of BUN, LDH, and creatinine. The results in  
214 Table 2 showed that treatment with 8 mg kg<sup>-1</sup> bw d<sup>-1</sup> of furan for 7 days, the activity of LDH and  
215 the levels of BUN and creatinine were significantly increased, compared to control group (*p*<0.05).  
216 Treatment with 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> of apigenin for 14 days prevented the LDH activity to 26.3%,  
217 the BUN level to 23.2%, and the creatinine level to 36.8% in the serum, respectively.

#### 218 **Antioxidant activity of apigenin**

219 The antioxidant activity of apigenin was evaluated using five methods, and the results were  
220 shown in Table 3. The ABTS radical scavenging ability, •OH-scavenging ability, DPPH radical  
221 scavenging ability, •O<sub>2</sub><sup>-</sup> scavenging ability and lipid oxidation inhibition increased with the  
222 increase concentration of apigenin. The *IC*<sub>50</sub> values of various antioxidant assays were used to  
223 evaluate the antioxidant level of apigenin. The *IC*<sub>50</sub> values of apigenin concentration for the DPPH  
224 radical, ABTS radical, •OH, and •O<sub>2</sub><sup>-</sup> were 6.42, 5.61, 0.004, and 0.01 mg mL<sup>-1</sup>, respectively.

#### 225 **Discussion**

226 Our study provides the first evidence of a potential protective effect of apigenin on the toxicity  
227 induced by furan in Balb/C mice model. This protection is related to the concentration of apigenin  
228 ranging from 5 to 20 mg kg<sup>-1</sup> bw d<sup>-1</sup>.

229 In recent studies, the reactive oxygen species (ROS), such as superoxide anion (•O<sub>2</sub><sup>-</sup>), hydrogen

Formatted: Font color: Auto

Formatted: Font color: Auto

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

230 peroxide (H<sub>2</sub>O<sub>2</sub>), and hydroxyl radical (•OH), have been associated with many diseases in the  
231 human body.<sup>23</sup> In the current paper, we first studied the effect of furan and apigenin on the ROS in  
232 male mice model. The data revealed that treating mice with furan of 8 mg kg<sup>-1</sup> bw d<sup>-1</sup> for 7 days  
233 significantly increased the content of ROS in the serum (*p*<0.05, Fig.1), the ROS level was  
234 2.6-fold higher than that in the control group. After treatment with apigenin, the ROS content was  
235 decreased with a clear dose-dependency trend. In the vitro experiment on the determination of  
236 antioxidant activity of apigenin, lower *IC*<sub>50</sub> values indicated that apigenin had excellent  
237 antioxidant properties. Among the assays, the best inhibiting capacity of apigenin was observed in  
238 •OH (0.004 mg mL<sup>-1</sup>). In lipid oxidation inhibition assay, the general ability of apigenin to prevent  
239 lipid oxidant was tested, and a 32.91 ± 1.25% lipid oxidation inhibition was observed, which  
240 showed the apigenin also could inhibit lipid oxidation effectively. That is to say, apigenin has  
241 great ability to free radical scavenging, such as •OH, and •O<sub>2</sub><sup>-</sup> free radical, and it is maybe an  
242 important reason for apigenin to decrease the ROS content induced by furan.

243 The oxidative damage of furan was also evaluated by determining the activities of GST, SOD,  
244 MPO, and the changes of GSH and MDA levels in the liver and kidney of furan-treated mice.  
245 GSH is as an essential intracellular reducing substance for the maintenance of thiol groups on  
246 intracellular proteins and antioxidant molecules in living organisms.<sup>24</sup> Furan is metabolized by  
247 cytochrome P450 enzymes to its major metabolite cis-2-butene-1,4-dial (BDA),<sup>25</sup> which has been  
248 shown to react with cellular nucleophiles such as GSH and amino acids and to cause cross-links  
249 between thiols and amino groups.<sup>26</sup> GSH plays an important role in protecting several tissues and  
250 cell lines against injuries by oxidants and reactive electrophiles.<sup>27</sup> GSH activities both in the liver  
251 and in the kidney treated by furan were significantly decreased (*p*<0.05), showed that the GSH

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

252 activities were maybe strained by the formation of cross-links between BDA and GSH. GST,  
253 previously known as ligandins, comprises a family of eukaryotic and prokaryotic phase II  
254 metabolic isozymes best known for their ability to catalyze the conjugation of the reduced form of  
255 GSH to xenobiotic substrates for the purpose of detoxification. GST activity is a sensitive factor  
256 that reflects the damage of the body. We observed a significant decrease in GST activity both in  
257 the liver and in the kidney of furan-treated mouse compared to the control group ( $p < 0.05$ ),  
258 showing that furan had damaged the liver hepatocyte and kidney to some extent. As GST increases  
259 the solubility of hydrophobic substances, it also plays an important role in the storage and  
260 excretion of xenobiotics. Compounds that increase the activity of GST, which metabolizes toxic  
261 compounds to non-toxic, protect the liver.<sup>28</sup> In the current study, GST activity was inhibited by the  
262 addition of furan in the body, showing that furan could induce the damage on the important  
263 detoxification enzymes and further cause damage to the body. However, the addition of apigenin  
264 has inhibited the decrease of GSH level and GST activity induced by furan, showing that apigenin  
265 paly a role on reduce the damage from furan. This results are consistent with the study of Yang et  
266 al., which research about the protective effect of apigenin on mouse acute liver injury induced by  
267 acetaminophen and its associate with increment of hepatic glutathione reductase activity.<sup>21</sup>  
268 Antioxidant enzymes such as SOD are capable of catalyzing the dismutation of superoxide ( $\bullet\text{O}_2^-$ )  
269 into oxygen and hydrogen peroxide. Thus, they are an important antioxidant defense in nearly all  
270 cells exposed to oxygen and often used to evaluate the oxidative stress of organism.<sup>29</sup> Furan with  
271 a concentration of  $8 \text{ mg kg}^{-1} \text{ bw d}^{-1}$  for 7 days significantly decreased the activities of SOD in the  
272 liver and kidney of treated mice compared to the control group ( $p < 0.05$ ), shown that furan  
273 occurred the oxidative stress. Myeloperoxidase (MPO) is a peroxidase enzyme, which is an

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Field Code Changed

Field Code Changed

274 endogenous lysosomal enzyme that removes H<sub>2</sub>O<sub>2</sub> and catalyzes the formation of toxic  
275 hypochlorous acid. The current study revealed that the MPO activities were significantly increased  
276 by furan in its current concentration. MPO and its oxidative products play key roles in the lipid  
277 peroxidation in liver damage. Lipid peroxidation generates a complex variety of products, many of  
278 which are reactive electrophiles. Some of these react with protein and DNA and cause toxicity and  
279 mutagenicity.<sup>30</sup> Some peroxidation study showed the correlation between the levels of neutrophil  
280 and MDA, the latter was an indicator of free radical-mediated lipid peroxidation damage.<sup>31</sup> MDA  
281 is the end product of lipid peroxidation. Elevated liver MDA levels imply that enhanced peroxidation  
282 causes tissue damage and the breakdown of antioxidant defense mechanisms, thus preventing the  
283 formation of superabundant free radicals.<sup>32</sup> Our data showed the treatment with furan caused  
284 significantly increased MDA levels compared with the control group (Fig. 2). In our study, the  
285 food contaminant of furan has the ability to enhance the oxidative stress and ROS content in the  
286 mice, it could know from the changes of the abilities of GST, SOD, MPO, and the levels of GSH,  
287 MDA and ROS, which is consistent with the study of Cordelli et al.<sup>29</sup> they revealed from gene  
288 expression analysis that ROS/ oxidative stress production (Gstm1, Gstm3, Gyp4a10, and Cyp4a14)  
289 genes were significantly up-regulated in furan-treated mice with a concentration of 15 mg kg<sup>-1</sup> bw  
290 d<sup>-1</sup> for 28 days. Hickling et al.<sup>33</sup> also found that furan-induced changes in the expression of  
291 various genes were associated with oxidative stress, DNA damage, and cell cycle control. After the  
292 mice were treated with apigenin at 5, 10, and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup>, the activities of oxidative stress  
293 related enzymes, such as GSH, GST, and SOD, were increased with a dose-dependency trend.  
294 MPO enzymes are associated with the lipid peroxidation, which is regarded as one of the basic  
295 mechanisms of tissue damage caused by free radicals.<sup>34</sup> The general ability of apigenin to prevent

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

296 lipid oxidant was  $(32.91 \pm 1.25)\%$  of lipid oxidation inhibition, showing the apigenin also have  
297 ability to inhibit lipid oxidation. This might be an effective inhibitor in reducing the MPO abilities  
298 and MDA formation. Singh et al.<sup>35</sup> also found that apigenin is able to quench the lipid peroxidation  
299 chain and is capable of shielding the membrane from free radicals which cause injuries.

300 Cytokines play important roles in the normal physiology of cells. They are related with the  
301 immune response, inflammation, and tissue injury or repair.<sup>36</sup> Our data about cytokines including  
302 TNF- $\alpha$ , (IL)-1 $\beta$ , (IL)-6 and (IL)-10, showed that furan activated inflammatory cells and  
303 subsequently amplified the inflammatory response by releasing various cytokines. When the mice  
304 were intragastrically given apigenin, the contents of TNF- $\alpha$ , (IL)-1 $\beta$  and (IL)-6 were markedly  
305 decreased and the (IL)-10 level was increased in mice serum. These results suggested that  
306 apigenin could alleviate tissue injury caused by furan through suppressing inflammatory response.

307 Furan could induce inflammatory response by increasing expression of cytokines and other  
308 inflammation-associated genes, such as (IL)-1 $\beta$ , (IL)-6, and (IL)-10, as was confirmed by our  
309 present study.<sup>12, 34, 37</sup> Gerritsen et al and Takano-Ishikawa et al<sup>38,39</sup> revealed that apigenin

310 inhibited the expression of inflammation-related molecules, such as intercellular adhesion  
311 molecule-1, vascular cell adhesion molecule-1, and E-selectin, induced by TNF- $\alpha$  and IL-1 $\alpha$ . Lee

312 et al (2007)<sup>40</sup> studied that apigenin profoundly reduced the tumor necrosis factor- $\alpha$   
313 (TNF- $\alpha$ )-induced adhesion of monocytes to HUVEC monolayer, further suggesting that apigenin  
314 has significant anti-inflammatory activity that is involved in blocking NO-mediated COX-2

315 expression and monocyte adherence. Funakoshi-Tago et al<sup>41</sup> found that apigenin significantly  
316 inhibited TNF- $\alpha$ -induced NF- $\kappa$ B transcriptional activation. Similarly, in the study of Rithidech et

317 al,<sup>42</sup> apigenin at dosage of 10mg kg<sup>-1</sup> bw d<sup>-1</sup> significantly inhibited cytokines such as TNF, IL-1

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto



318 and IL-6 expression in vivo given to mice after irradiation. Man et al<sup>43</sup> demonstrated that all  
319 these anti-inflammatory effects induced by apigenin were likely attributed to its antioxidant  
320 properties. Our research showed that apigenin had great antioxidant abilities. The best inhibiting  
321 capacity of apigenin was observed in  $\bullet\text{OH}$  and  $\bullet\text{O}_2^-$ , which would contribute to the  
322 anti-inflammatory effect of apigenin on that induced by furan in mice model.

323 8-OHdG is a marker of oxidative damage, and mutations may arise from the formation of  
324 8-OHdG involving G·C→T·A transversions.<sup>44,45</sup> We found that 8-OHdG levels were dramatically  
325 enhanced by furan with a concentration of 8 mg kg<sup>-1</sup> bw d<sup>-1</sup> for 7 days compared to the control  
326 group ( $p < 0.05$ , Fig. 4). In the study of Hickling et al (2010),<sup>33</sup> there was a marked association  
327 between CYP2E1 expression and DNA oxidation (8-OHdG) in areas of centrilobular hepatocyte  
328 necrosis seen after a single dose of furan of 30 mg kg<sup>-1</sup> bw d<sup>-1</sup> daily doses per week for three  
329 months. After one month of recovery experiments from three-month treatment, 8-OHdG was still  
330 observed in areas of furan-induced cholangiofibrosis. The present study also demonstrated that  
331 apigenin could significantly decrease the level of 8-OHdG in furan-treated mice. We also found  
332 that the highest dose of apigenin (20 mg kg<sup>-1</sup> bw d<sup>-1</sup>) had the best protective effect ( $p < 0.05$ ).

333 Furan is a typical hepatotoxicity compound, and the liver is the main target organ of  
334 furan-induced toxicity in rats and mice with a clear dose-dependency and probably acting by a  
335 genotoxic mechanism.<sup>11</sup> In our present study, we evaluated the hepatic enzymes, such as ALT and  
336 AST, as the biochemical markers for the detection of early acute hepatic damage. Their increased  
337 levels in serum indicated the increased permeability and damage and/or necrosis of hepatocytes. In  
338 our present study, furan caused a significant increase in the activities of AST and ALT (Table 1),  
339 which was attributed to the severe damage of the tissue membrane. This results are consistent with

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

340 the study of Moser et al. and Hamadeh et al.<sup>46,47</sup> After an administration of apigenin, the activities  
341 of AST and ALT decreased in the serum of mice. Similarly, the increased level of LDH that is an  
342 intracellular enzyme in serum is an indicator of a cell damage.<sup>48</sup> The findings suggested apigenin  
343 was effective in preventing the furan-induced hepatocyte damage. We also evaluated the changes  
344 of BUN and creatinine levels of apigenin treated mice to study the kidney damage induced by  
345 furan. BUN is an indirect and rough measurement to the metabolic function of the liver and  
346 excretory function of the kidney. Furan could significantly increase the BUN content in the serum,  
347 which is consistent with the study of Gill et al.<sup>12</sup> Treatment with apigenin with the concentration  
348 of 5, 10, and 20 mg kg<sup>-1</sup> bw d<sup>-1</sup> could restrain the increase of BUN level compared to the  
349 furan-treated group. Similarly, we found a dramatically increase of creatinine levels in the mice  
350 treated by furan compared to the control group ( $p < 0.05$ ). While in the study of Gill et al.<sup>12</sup> who  
351 founded that creatinine was not affected in females, whereas in males it showed an increase linear  
352 trend with the furan concentration of 0.0, 0.03, 0.12, 0.5, 2.0, and 8.0 mg kg<sup>-1</sup> bw d<sup>-1</sup>. Apigenin  
353 significantly prevented the rises of creatinine levels in serum among the furan-treated mice,  
354 suggesting the apigenin potently protected against the kidney toxicity induced by furan.

### 355 Conclusion

356 In conclusion, this study was first to investigate the effects of apigenin on the toxicity induced  
357 by furan in mice model. By evaluating the ROS content, oxidative damage, cytokines, DNA  
358 damage, and liver and kidney damage, our data demonstrated that apigenin possessed a powerful  
359 protective capacity from the toxicity and damage induced by furan. Taken together, these results  
360 strongly suggest that apigenin is an effective agent to protect the exogenous toxic compound, such  
361 as furan, but further investigation will be needed to clarify the exact mechanisms. At least we can

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Font color: Auto

362 clear that taking food rich in apigenin or supplementing with apigenin might be health beneficial  
363 for the individuals who are at risk of furan toxicity.

364

#### 365 **Acknowledgements**

366 This work was supported by the Fund of National Basic Research Program of China (“973”  
367 Program, 2012CB720805), National High Technology Research and Development Program of  
368 China (“863” Project, 2011AA100806). Accordingly, the authors gratefully acknowledge the  
369 funds supports.

370

#### 371 **References**

372 1 US Food Safety Authority, 2004.

373 [http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/ChemicalContaminants/F](http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/ChemicalContaminants/Furan/ucm078469.htm)  
374 [uran/ucm078469.htm](http://www.fda.gov/Food/FoodSafety/FoodContaminantsAdulteration/ChemicalContaminants/Furan/ucm078469.htm)

375 2 A. Arisseto, E. Vicente, M. Ueno, and M.C. Toledo, *Toxicol. Let.*, 2010, **196S**, S332.

376 3 S. J. Wu, E.T. Wang, and Y. Yuan. *Food Chem. Toxicol.*, 2014, **64**, 34-40.

377 4 C.P. Perez Locas, and V.A. Yaylayan, *J. Agric. Food Chem.*, 2004, **52**, 6830-6836.

378 5 A. Beclaski, and S. Seaman, *J. AOAC. Int.*, 2005, **88**, 102-106.

379 6 A. Limacher, J. Kerler, T. Davidek, F. Schmalzried, and I. Blank, *J. Agric. Food Chem.*, 2008, **56**,  
380 3639-3647.

381 7 A. Owczared-Fendor, B. De Meuleaner, G. Scholl, A. Adma, F. van Lancker, G. Eppe, E. De  
382 Pauw, M. Scippo, and N. De Kimpe, *Food Chem.*, 2012, **133**, 816-821.

383 8 F. van Lancker, A. Adams, A. Owczarek-Fendor, B. De Meuienaer, and N. De Limpe., *J. Agric.*

Formatted: Font color: Auto

- 384 *Food Chem.*, 2011, **59**, 229-235.
- 385 9 M.S. Mariotti, K. Granby, J. Rozowski, F. Pedreschi, *Food Funct.*, 2013, **4**, 1001-1015.
- 386 10 IARC, Lyon, 1995, pp 3194-3407.
- 387 11 NTP (National Toxicology Program). 1993. NTP Technical report No. 402.
- 388 12 S. Gill, M. Kavanagh, M. Barker, M. Weld, E. Vavasour, Y. Hou, and G.M. Cooke, *Toxicol.*
- 389 *Pathol.*, 2011, **39**, 787-794.
- 390 13. G. Selmanoğlu, E. Karacaoğlu, A. Kiliç, E.A. Koçkaya, M.T. Akay, *Environ Toxicol*, 2012,**27**,
- 391 613-622.
- 392 14 L.L. Zhang, E.T. Wang, F. Chen, H.Y. Yan, and Y. Yuan, *Food Funct.*, 2013, **4**, 1229-1236.
- 393 15 L.L. Zhang, H.J. Zhang, Y.T. Miao, S.J. Wu, H.Q. Ye and Y. Yuan, *Food Chem. Toxicol.*,
- 394 2012, **50**, 3306-3312.
- 395 16 Y. Yuan, S.J. Wu, X. Liu, and L.L. Zhang, *Food Funct.*, 2013, **4**, 763-769.
- 396 17 C.S. Chung, Y. Jiang, D. Cheng, and D.F. Birt, *Mol. Carcinog.*, 2007, **46**, 773-782.
- 397 18 C.A. Franzen, E. Amargo, V. Todorovic, B.V. Desai, S. Huda, S. Mirzoeva, K. Chiu, B.A.
- 398 Grzybowski, T.L. Chew, K.J. Green, and J.C. Pellin, *Cancer Prev. Res.*, 2009, **2**, 830-843.
- 399 19 J.C. King, Q.Y. Lu, G. Li, A. Moro, H. Takahashi, M. Chen, V.L. Go, H.A. Reber, G. Eibl, and
- 400 O.J. Hines, *Biochim. Biophys. Acta.*, 2012, **1823**, 593-604.
- 401 20 S. Shukla, and S. Gupta, *Free Rad. Biol. Med.*, 2008, **44**, 1833-1845.
- 402 21 J.Yang, X.Y.Wang, J.Xue, Z.L.Xie, *Food Funct.*,2013,**4(6)**,939-943.
- 403 22 D.B. Muñoz-Márquez, G.C. Martínez-Ávila, J.E. Wong-Paz, R. Belmares-Cerda, R.
- 404 Rodríguez-Herrera, and C.N. Aguilar, *Ultrason. Sonochem.*, 2013, **20**, 1149-1154.
- 405 23 X.Wen, J.M. Wu, F.T. Wang, B.Liu, C.H.Huang, Y.Q.Wei. *Free Radical Bio*

- 406 *Med.*,2013,**65**,402-410.
- 407 24 L.A. Peterson, M.E. Cummings, C.C. Vu, and B.A. Matter, , *Drug Metab. Dispos.*, 2005, **33**,
- 408 1453-1458.
- 409 25 T. Chen, T. D. Williams, A. Mally, C. Hamberger, L. Mirbahai, K. Hickling and J. K. Chipman,
- 410 *Toxicology.*, 2012, **292**, 63-70.
- 411 26 K.J. Lee, and H.G. Jenog, *Food Chem. Toxicol.*, 2002, **40**, 517-525.
- 412 27 X.Q. Shan, T.Y. Aw, D.P. Jones, *Pharmacol. Ther.*, 1990, **47**, 61–71.
- 413 28 C.M. Liu, J.Q. Ma, and Y. Lou, *Food Chem. Toxicol.*, 2010, **48**, 2809-2817.
- 414 29 A. Belboul, C. Lofgren, C. Storm, and M. Jungbeck, *Eur. J. Cardiothorac. Surg.*, 2000, **17**,
- 415 580-586.
- 416 30 L.J. Marnett, *Mutat Res.*,1999, **424**,83–95.
- 417 31 E. Cordelli, P. Leopardi, P. Villani, F. Marcon, C. Macii, S. Caicla, E. Siniscalchi, L. Conti, P.
- 418 Eleuteri, F. Malchiodi-Albedi, and R. Crebelli, *Mutagenesis.*, 2010, **25**, 305-314.
- 419 32 Y.W. Hsu, C.F.Tsai, W.K.Chen, *Food Chem. Toxicol.*,2009, **47**, 2281–2288.
- 420 33 K.C. Hickling, J.M. Hitchcock, V. Oreffo, A. Mally, T.G. Hammond, J.G. Evans, J.K. Chipman,
- 421 and *Toxicol. Pathol.*, 2010, **38**, 230-243.
- 422 34 H. Eserbauer, and R.J. Schaur, *Free Rad. Biol. Med.*, 1991, **11**, 81-128.
- 423 35 J.P.V. Singh, K. Selvendiran, S.M. Banu, R. Padmavathi, and D. Sakthisekaran, *Phytomedicine.*,
- 424 2004, **11**, 309-314.
- 425 36 L.A. DeCicco, L.E. Rikans, C.G.Tutor. K.R. Hornbrook, *Toxicol Lett.*, 1998, **98**,115–121.
- 426 37 S. Moro, J.K. Chipman, J.W. Wegener, C. Hamberger, W. Dekant, and A. Mally, *Mol. Nutr.*
- 427 *Food Res.*,, 2012, **56**, 1197-1211.

- 428 38 M.E. Gerritsen, W.W. Carley, G.E. Ranges, C.P. Shen, S.A. Phan, and C.A. Perry, *Am. J.*  
429 *Pathol.*, 1995, **147**, 278-292.
- 430 39 Y. Takano-Ishikawa, Y.M. Goto, and K. Yamaki, *Phytother. Res.*, 2003, **17**, 1224-1227.
- 431 40 J. Lee, H.Y. Zhou, S.Y. Cho, Y.S. Kim, Y.S. Lee, and C.S. Jeong, *Arch. Pharm. Res.*, 2007, **30**,  
432 1318-1327.
- 433 41 M. Funakoshi-Tago, K. Nakamura, K. Tago, T. Mashino, and T. Kasahara, *Int.*  
434 *Immunopharmacol.*, 2011, **11**, 1150-1159.
- 435 42 K.N. Rithidech, M. Tugiai, P. Reunqpatthanaphong, L. Honikel, and S.R. Simon, *Mutat. Res.*,  
436 2012, **749**, 29-38.
- 437 43 M.Q. Man, M. Hupe, R. Sun, G. Man, T. Mauro, and P.M. Elias, *Evid-Based Compl Alt.*, 2012,  
438 Article ID 912028, 1-7.
- 439 44 H. Kasai, *Mut. Res.*, 1997, **387**, 147-163.
- 440 45 M. Moriya, *P. Natl. Acad. Sci. USA.*, 1993, **90**, 1122-1126.
- 441 46 G.J. Moser, J. Foley, M. Burnett, T.L. Goldsworthy, R. Maronpot, *Exp Toxicol Pathol.*, 2009,  
442 **61**, 101-111.
- 443 47 H.K. Hamadeh, S. Jayadev, E.T. Gaillard, Q. Huang, R. Stoll, K. Blanchard, J. Chou, C.J.  
444 Tucker, J. Collins, R. Maronpot, P. Bushel, C.A. Afshari, *Mutat Res.*, 2004, **549**, 169-183.
- 445 48 K. A. Kim, W. K. Lee, J. K. Kim, M. S. Seo, Y. Lim, Y. Lee, and Y. Chung, *Int. Arch Occup.*  
446 *Environ. Health*, 2001, **74**, 9-15.

447

448

449

450 Figure captions:

451 Fig. 1 Effects of apigenin on ROS content in the serum of furan-treated mice.

452 All values are expressed as means  $\pm$  standard deviation (n = 8). Values in the same with  
453 different superscript upper case letters are significantly ( $p < 0.05$ ) different.

454

455 Fig.2 Effects of apigenin on the activities of GSH, GST, SOD, MPO, and MDA content in the liver  
456 and kidney of furan-treated mice. (A) GSH; (B) GST; (C) SOD; (D) MPO; (E) MDA.

457 All values are expressed as means  $\pm$  standard deviation (n = 8). Values in the same with  
458 different superscript upper case letters are significantly ( $p < 0.05$ ) different.

459

460 Fig.3 Effects of apigenin on 8-OHdG content in the serum of furan-treated mice.

461 All values are expressed as means  $\pm$  standard deviation (n = 8). Values in the same with  
462 different superscript upper case letters are significantly ( $p < 0.05$ ) different.

463

464

465

466 Table captions:

467 Table 1 Effects of apigenin on the content of (IL)-6, (IL)-10, (IL)-1 $\beta$ , and TNF- $\alpha$  in the serum of  
468 furan-treated mice.

469

470 Table 2 Effects of apigenin on activity of AST, ALT and LDH, as well as levels of BUN and  
471 creatininein in the serum of furan-treated mice.

472

473 Table 3 Antioxidant activity of apigenin by scavenging free radicals.


474

475




476

477



478

479 Fig. 1




485

486 | Fig. 2

Field Code Changed

Field Code Changed

487



488

489

490

Fig. 3

Table 1

Groups	IL-6 (pg mL <sup>-1</sup> )	IL-10 (pg mL <sup>-1</sup> )	IL-1 $\beta$ (pg mL <sup>-1</sup> )	TNF- $\alpha$ (pg mL <sup>-1</sup> )
Control	32.46 $\pm$ 0.67 <sup>a</sup>	152.30 $\pm$ 3.42 <sup>a</sup>	37.99 $\pm$ 1.41 <sup>a</sup>	188.75 $\pm$ 0.73 <sup>a</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	82.08 $\pm$ 0.94 <sup>b</sup>	103.99 $\pm$ 4.18 <sup>b</sup>	93.33 $\pm$ 2.05 <sup>b</sup>	351.50 $\pm$ 2.05 <sup>b</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (5 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	71.42 $\pm$ 1.03 <sup>b</sup>	109.16 $\pm$ 5.57 <sup>b</sup>	84.62 $\pm$ 2.73 <sup>b</sup>	302.95 $\pm$ 2.35 <sup>c</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (10 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	58.87 $\pm$ 1.08 <sup>c</sup>	123.21 $\pm$ 3.56 <sup>c</sup>	62.15 $\pm$ 0.52 <sup>c</sup>	272.21 $\pm$ 1.34 <sup>d</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (20 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	46.67 $\pm$ 0.89 <sup>ac</sup>	144.64 $\pm$ 3.41 <sup>a</sup>	52.45 $\pm$ 1.08 <sup>c</sup>	242.63 $\pm$ 2.23 <sup>c</sup>

All values are expressed as means  $\pm$  standard deviation (n = 8). Values in the same column with different superscript upper case letters are significantly (p < 0.05) different.

Table 2

Groups	AST (U L <sup>-1</sup> )	ALT (U L <sup>-1</sup> )	LDH (U L <sup>-1</sup> )	BUN (mg L <sup>-1</sup> )	Creatinine (μmol L <sup>-1</sup> )
Control	8.98±0.37 <sup>a</sup>	12.45±0.82 <sup>a</sup>	350.14±1.76 <sup>a</sup>	87.41±0.62 <sup>a</sup>	60.18±0.35 <sup>a</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	27.01±0.88 <sup>b</sup>	30.80±1.37 <sup>b</sup>	489.81±1.65 <sup>b</sup>	119.20±0.39 <sup>b</sup>	101.75±1.36 <sup>b</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (5 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	21.95±0.53 <sup>c</sup>	25.84±0.53 <sup>b</sup>	423.90±2.30 <sup>c</sup>	113.69±0.70 <sup>b</sup>	87.18±1.80 <sup>c</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (10 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	17.40±1.02 <sup>c</sup>	19.63±0.35 <sup>c</sup>	391.18±1.04 <sup>d</sup>	103.49±0.81 <sup>c</sup>	76.45±1.39 <sup>c</sup>
Furan (8 mg kg <sup>-1</sup> bw d <sup>-1</sup> ) + Apigenin (20 mg kg <sup>-1</sup> bw d <sup>-1</sup> )	12.79±0.94 <sup>d</sup>	14.53±0.65 <sup>a</sup>	361.20±1.15 <sup>a</sup>	91.49±1.28 <sup>a</sup>	64.35±1.00 <sup>a</sup>

All values are expressed as means ± standard deviation (n = 8). Values in the same column with different superscript upper case letters are significantly (p < 0.05) different.

Table 3

Free radical	Concentration apigenin (mg mL <sup>-1</sup> )	Scavenging Rate (%)	<i>IC</i> <sub>50</sub> (mg mL <sup>-1</sup> )
DPPH	1	43	6.42
	5	44	
	10	52	
	15	72	
ABTS	2	17	5.61
	4	47	
	6	59	
	8	60	
•OH	0.001	9	0.004
	0.002	38	
	0.004	49	
	0.006	71	
•O <sub>2</sub> <sup>-</sup>	0.03	6	0.01
	0.06	11	
	0.09	23	
	0.12	65	